Clinical trials in China are getting attention at an international oncology gathering in Chicago. China’s surging biotechnology industry is fueling alarm that U.S. dominance in the field is waning.

de la Fuente-Nunez is a presidential associate professor at the University of Pennsylvania. Skinner is CEO of the AMR Action Fund. Of all the areas of drug development that artificial intelligence has ...

Researchers are increasingly using AI to accelerate the search for treatments for neurological conditions such as Alzheimer’s ...

Evosep announces the launch of Evosep Proteomics, an ecosystem designed to standardize and scale LC-MS-based proteomics for research and pharmaceutical drug development.

Discover how quality-driven drug development and AI accelerate safer medicines, reduce risk, and improve patient outcomes.

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is also the author of the morning Pharmalittle newsletter ...

Decades of reliance on the antibiotic rifampicin have fueled the rise of drug-resistant Mycobacterium tuberculosis (Mtb). But ...

Antibiotics are a crucial tool in the fight against bacterial infections. But the World Health Organization has long warned that we are facing an antibiotic crisis. Bacteria can easily adapt, evolve, ...

Although the past decade has been marked by lack of innovation in the field of antibiotics development, that trend is changing, according to data from Reportlinker. According to the data, 109 ...

This article is also available as a pdf version. Antimicrobial resistance (AMR) to existing medicines creates one of the biggest dangers for global health. According to the Antimicrobial Resistance ...